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Ten new meﬂoquine–oxazolidine derivatives, 4-[(1S,8aR)-3-(aryl)hexahydro[1,3]oxazolo[3,4-a]pyridin-
1-yl]-2,8-bis(triﬂuoromethyl)quinoline (1: aryl = substituted phenyl) and 4-[(1S,8aR)-3-(heteroaryl)
hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline [2: heteroaryl = 5-nitroth-
ien-2-yl (2a); 5-nitrofuran-2-yl (2b) and 4H-imidazol-2-yl) (2c)], have been synthesized and evaluated
against Mycobacterium tuberculosis. Compounds 1f (aryl = 3-ethoxyphenyl), 1g (Ar = 3,4,5-(MeO)3-C6H2)
and 2cwere slightly more active than meﬂoquine (MIC = 33 lM) with MICs = 24.5, 22.5 and 27.4, respec-
tively, whereas compounds 1e (aryl = 3,4-(MeO)2-C6H3) and 2a (MICs = 11.9 and 12.1 lM, respectively)
were ca. 2.7 times more active than meﬂoquine, with a better tuberculostatic activity than the ﬁrst line
tuberculostatic agent ethambutol (MIC = 15.9). The compounds were also assayed against the MDR strain
T113 and the same MICs were observed. Thus the new derivatives have advantages over such anti-TB
drugs as isoniazid, rifampicin, ethambutol and oﬂoxacin, for which this strain is resistant. The most active
compounds were not cytotoxic to Murine Macrophages Cells in a concentration near their MIC values.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Widespread dissemination of multidrug-resistant tuberculosis
(MDR-TB) and extensively drug-resistant TB (XDR-TB) is one of
the major health issues faced by a number of countries. These
forms of TB do not respond to standard treatments with ﬁrst-line
anti-TB drugs and can take up to two years or more to treat with
other drugs that are less potent, more toxic and much more expen-
sive.1 Thus the development of new substances, which possess dif-
ferent mechanisms of action and improved effects when compared
with the currently available drugs, is regarded as an urgent global
health priority.
We have been particularly interested in the development of new
meﬂoquine (MFL) derivatives for use in TB treatment. Beyond its+552125602518.
.N. de Souza).
evier OA license.irrefutable ability in malaria treatment and prophylaxis, MFL has
a broad range activity against Gram-positive and Gram-negative
bacteria.2 Furthermore as shown by Bermudez and coworkers,3
MFL can inhibit the growth ofMycobacterium species in aMIC range
of 21.1–42.1 lM.
Studies utilizing the bacteria Streptococcus pneumoniae dis-
played that the prokaryotic target of MFL is the c subunit of the
cytoplasmatic membrane sector F0 of the enzyme F0F1 ATPase.4
Furthermore, it was observed that the exposure of Mycobacterium
tuberculosis to MFL at a 4 MIC concentration lead to upregulation
of the expression of gene coding membrane proteins, suggesting
that the target for meﬂoquine in M. tuberculosis is in the cell wall.5
However, there are no data in the literature showing molecular
interactions of meﬂoquine with its target.
We recently reported the synthesis and the antitubercular
evaluation against M. tuberculosis H37Rv (ATCC 27294) of several
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dro[1,3] oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)
quinoline, 1, obtained from meﬂoquine and monosubstituted
benzaldehydes, see Scheme 1.6 Compounds bearing electron-
releasing substituents, for example, (1k: aryl = 2-MeOC6H4), dis-
played appreciable activities, being more active than meﬂoquine
and displaying an activity comparable with that of the ﬁrst line
tuberculostatic agent ethambutol.
We have continued our studies with an investigation of deriva-
tives, which includes compounds containing additional electron
releasing groups, for example, (1: aryl = 3,4-dimethoxyphenyl and
3,4,5-trimethoxyphenyl) and heteroaryl units, 1-(2,8-bis(triﬂuoro-
methyl)quinolin-4-yl)-3-(aryl)-hexahydro-1H-oxazolo[3,4-a]pyrid
ine, (2: heteroaryl = 5-nitrothien-2-yl, 5-nitrofuran-2-yl and 4H-
imidazol-2-yl). Furthermore, we have tested the compounds, found
to be most active against M. tuberculosis H37Rv (ATCC 27294), on
the multidrug-resistant tuberculosis strain T113.
The heteroaryl derivatives were chosen since compounds bear-
ing such moieties display very important roles in the treatment of
bacterial infections. Classical examples are the antimicrobial
agents: nitrofurantoin, metronidazole and nitazoxanide.7 Another
illustration of the importance of heterocyclic groups in antibacte-
rial compounds is shown by the antibiotic ranbezolid, an oxazolid-
inone, which contains a nitrofuryl substituent, and possesses an
expanded spectrum of activity compared to linezolid.8 Speciﬁcally
for TB, the nitroaromatic class of antibiotics is one of the few that
have shown activity against latentM. tuberculosis. The most impor-
tant examples are PA-824 and OPC-67683, currently in clinical trial
for TB treatment.9
2. Results and discussion
2.1. Chemistry
The synthesis of meﬂoquine–oxazolidine derivatives, 1 and 2, is
summarized in Scheme 1. Initially, the reactions of meﬂoquine
with the arenealdehydes were carried out in toluene, utilizing a
Dean–Stark apparatus. However, in several cases, mainly when
electron donating groups were present in the aromatic ring, a
low reactivity was observed and, even after 48–72 h, much starting
material had not reacted. Better results were reached when the
reactions were carried out in the presence of molecular sieves
4 Å and amberlyst 15, in toluene. For the syntheses of compounds
1a–d and 2a–c an excess of the aldehyde was used with complete
consumption of meﬂoquine observed by TLC after 24–48 h. The
reaction mixtures were ﬁltered through Celite and concentrated
to yield a semi-solid, which was triturated with cold ethanol, in or-
der to produce the pure product. Compounds 1e–g were very sol-
uble in ethanol and puriﬁcation by column chromatography wasN
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Scheme 1. Synthesis of meﬂoqurequired. In these cases, an excess of meﬂoquine was used, since
the chromatographic separation was found to be easier in the ab-
sence of any aldehyde.
As observed in our previous work,6 ring formation to give the
oxazolidine system does not involve reaction at either of the chiral
centres in the racemic erythro meﬂoquine reagent and hence the
stereochemistries at these sites are preserved in the products.
Two new chiral centres are generated in the oxazolidine product
from the benzaldehyde carbonyl carbon and the piperidinyl nitro-
gen atom in meﬂoquine. As a racemic meﬂoquine reagent was
used, so the product is formed as a racemic mixture. In most cases,
except compound 2a, the products were enantiomers with stereo-
chemistries at C9, C10, C17 and N2 of (R⁄), (S⁄), (S⁄) and (R⁄), respec-
tively. However, compound 2a was formed as a mixture of
diastereoisomers, as observed from the 1H NMR spectrum, which
displayed duplicated signals.
All compounds were identiﬁed by elementary analysis, 1H NMR,
13C NMR, IR spectra and MS data, and additionally in the case of 1g
by X-ray crystallography. The chemical shifts, multiplicities and
coupling constants in the 1H NMR spectra plus COSY experiments
conﬁrmed the proposed structures. For the oxazolidine ring, the
protons, H110 appear as a characteristic singlet in the range
5.75–4.89 ppm. In the IR spectra, characteristic signals at
1311–1305 cm1 were observed for the C–O axial deformation
and at 1266–1080 cm1 for the C–F axial deformation. Usually,
more than one signal was observed for the CF3 group as a result
of the presence of rotational isomers.
The single crystal structure determination of 1g, recrystallized
from EtOH, was undertaken to conﬁrm its stereochemistry and con-
formation.10–12 The triclinic space group, P-1, was assigned, which
being a non-chiral space group indicated that both enantiomers
of 1g are present in the single crystal examined. The chiral centres
at C9, C10, C17 and N2 are assigned the stereochemistries (R⁄), (S⁄),
(S⁄) and (R⁄), respectively. Figure 1 shows the atom arrangements in
the (R), (S), (S), (R)-enantiomer. The bond angles and bond lengths
are all in the expected regions. The piperidinyl ring has a near per-
fect chair conformation, while the ﬁve-membered 1,3-oxazolidine
ring has an envelope shapewith ﬂap at the nitrogen atom. The angle
between the plane of the quinoline moiety and (a) the plane of the
phenyl ring is 35.9 Å and (b) with the best plane through the pipe-
ridinyl and oxazolidenyl rings is 87.9 Å. The only intermolecular
interactions are weak C–H  O and C–H  F intermolecular hydro-
gen bonds and p  p stacking interactions.
2.2. Antimycobacterial activity against M. tuberculosis H37Rv
(ATCC 27294)
The anti-mycobacterial activities of derivatives 1a–g and 2a–c
are shown in Table 1. All compounds were assessed againstF3 N
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Figure 1. (a) Atom numbering scheme and atom arrangement for 1g. Probability ellipsoids are drawn at the 50% level; (b) Conformation of 1g. Hydrogen atoms have been
omitted for clarity.
Table 1
Antimycobacterial activities againstM. tuberculosis H37Rv (ATCC 27294) and MDR-TB
strain T113
Compound MICa (lM) M. tuberculosis
H37Rv(ATCC 27294)
MICa,b (lM)
MDR-TB strain
T113
1a: Ar = 2,3-ClC6H3 >250 n.d.
1b: Ar = 3,4-ClC6H3 >250 n.d.
1c: Ar = 2,4-ClC6H3 >250 n.d.
1d: Ar = 2,6-ClC6H3 >250 n.d.
1e: Ar = 2,3-
(MeO)2C6H3
11.9 11.9
1f: Ar = 3-EtOC6H4 24.5 24.5
1g: Ar = 3,4,5-
(MeO)3C6H2
22.5 22.5
1h: Ar = 4-FC6H4 25.8c 25.8
1i: Ar = 2-HOC6H4 25.9c 25.9
1j: Ar = 4-HOC6H4 25.9c 25.9
1k: Ar = 2-MeOC6H4 12.6c 12.6
1l: Ar = 3-MeOC6H4 25.2c 25.2
1m: Ar = 4-MeOC6H4 25.2c 25.2
1n: Ar = C6H5 26.8c 26.8
2a: X = S, Y = CH,
R = NO2
12.1 12.1
2b: X = O, Y = CH,
R = NO2
99.8 99.8
2c: X = Y = N, R = H 27.4 27.4
Meﬂoquine 33 33
Ethambutol 15.9 61.2
a Minimum inhibitory concentration.
b Drug resistance proﬁle: MDR strain resistant to isoniazid, rifampicin,
ethambutol and oﬂoxacin.
c Data from Ref. 6.
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Alamar Blue assay (MABA),14 a non-toxic methodology which
employs a thermally-stable reagent and shows good correlation
with proportional and BACTEC radiometric methods.15,16 The as-
says were realized in triplicate and, in each case, a racemic mixture
of the synthesized compound was used, with exception of com-
pound 2a, where the diastereoisomeric mixture was assayed.
In conﬁrmation of the earlier ﬁndings, compounds, 1, having
electron donating substituent in the phenyl ring, exhibited excel-
lent biological active.6 The most active of the new compounds
was the dimethoxy derivative (1e), with a MIC value of 11.9 lM,
2.8 times greater than that of the parent meﬂoquine (MIC = 33 lM).
The new compound 3-ethoxy derivative (1f) had a similar activity
to that previously reported for the 3-methoxy derivative (1l)6
(24.5 and 25.2 lM, respectively), indicating that the longer alkyl
chain length scarcely effected the biological activity. It is important
to mention that the synthesis of the 2-ethoxy derivative was alsoattempted since, in our previous work,6 the 2-methoxy derivative
was identiﬁed as the most active compound. However, after several
hours of reaction time, formation of the reaction product was not
observed. This lack of reactivity can be attributed to the combina-
tion of the strong electron-donation character of the ethoxy group
with steric effects caused by the presence of a longer alkyl chain
in ortho position. The tri-substituted derivative (1g), while active,
was less so than the dimethoxy derivative (1e). None of the dichlo-
rophenyl compounds 1a-d showed anti-tubercular activity, in
keeping with the previous ﬁnding that compounds having electron
withdrawing groups, such as chloro, had poor activities.
Among the three heteroaromatic compounds synthesized, 2a
displayed the best activity, with a MIC of 12.1 lM. However, the
isosteric displacement of the 2-nitrothienyl moiety by a 2-nitrofu-
ryl yielded the less active compound 2b, with a MIC of 99.8 lM.
The imidazole derivative 2c displayed a modest activity with a
MIC of 27.4 lM.
2.3. Evaluation against a MDR-TB strain
After evaluation against the standard strain of M. tuberculosis
H37Rv (ATCC 27294), the active compounds, 1, mainly the alkoxy
derivatives, but also 1h and 1n, were tested against a MDR-TB
strain, see Table 1. This strain, T113, was isolated from a clinical
case of pulmonary tuberculosis in the city of Rio de Janeiro and
belonged to the collection of the Bacteriology and Bioassay Labora-
tory—Instituto de Pesquisa Clínica Evandro Chagas—PEC—FIOCRUZ.
The utilization of this strain was motivated by the fact that it is
resistant to the main drugs utilized in the ﬁrst line TB treatment
(isoniazid, rifampicin and ethambutol) and one important ﬂuoro-
quinolone utilized in the second line TB treatment (oﬂoxacin).
The susceptibility proﬁles were evaluated though the non radio-
metric Bactec MGIT 960 (BT960) system and the micro plate
Alamar Blue assay (MABA), at two laboratories in an inter-
laboratory control program. Of some signiﬁcance, the same MICs
were observed as found for the standard strain H37Rv (ATCC
27294). Thus the new derivatives differ from isoniazid, rifampicin,
ethambutol and oﬂoxacin, for which MDR strain T113 is resistant.
Considering the alarming situation of MDR and XDR-TB, the identi-
ﬁcation of substances which can target these strains can be consid-
ered of great importance for the development of new anti-TB drugs.
2.4. Cell viability assay
The cellular viability in the presence and absence of test
compounds was determined by Mosmans’s MTT
Table 2
Data of cytotoxic effects of test compounds on Murine Macrophages Cells 18 h after
the treatment
Compound % Cell viability/doses (lM)
100 10 1
1a 100 100 100
1b 100 100 100
1c 98 100 100
1d 59 92 93
1e 100 100 100
1f 95 100 100
1g 97 100 100
2a 100 100 100
2b 100 100 100
2c 100 100 100
Meﬂoquine 70 81 95
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mide; Merck) microcultured tetrazolium assay17 at three different
concentrations, 100, 10 and1 lM.The resultswere expressedasper-
centage cell viability (Table 2). The active compoundswerenot cyto-
toxic to the host cells at concentrations near the MIC. However,
meﬂoquine displayed a low cytotoxicity.3. Conclusion
In this work, a series of meﬂoquine–oxazolidine derivatives,
containing phenyl and heteroaryl substituents on the oxazolidine
nucleus, has been synthesized and tested against M. tuberculosis.
Among them, six compounds displayed modest to good antimico-
bacterial activities in the in vitro microplate Alamar Blue assay. A
slight improvement in the biological activity was observed for
compounds 1f, 1g and 2c when compared with the prototype mef-
loquine. On the other hand, compounds 1e and 2a (MICs = 11.9 and
12.1 lM, respectively) were around 2.7 times more active than
meﬂoquine. The compounds were evaluated against a MDR-TB
strain and the same MICs were observed. The cell viability assay
displayed that the compounds were not cytotoxic to Murine Mac-
rophages Cells in a concentration near the MIC. When compared
with the ﬁrst line tuberculostatic agent ethambutol (MIC = 15.9),
the meﬂoquine–oxazolidine derivatives 1e and 2a can be consid-
ered an important start point in the development of new tubercu-
lostatic drugs.4. Experimental
4.1. General procedures
Melting points were determined on a Buchi apparatus and are
uncorrected. Infrared spectra were recorded on a Thermo Nicolet
Nexus 670 spectrometer as potassium bromide pellets and
frequencies are expressed in cm1. Mass spectra (ESI assay insolu-
tion of ammonium chloride) were recorded on Micromass ZQ
Waters mass spectrometer. Elementary analyses were performed
on a Perkin-Elmer 2400 CHN Elemental Analyser and a microbal-
ance AD-4 autobalance Perkin-Elmer. NMR spectra were recorded
on a Bruker Avance 400 operating at 400.00 MHz (1H) and
100.0 MHz (13C) and Bruker Avance 500 spectrometer operating
at 500.00 MHz (1H) and 125.0 MHz (13C), in deuterated acetone.
Chemical shifts are reported in ppm (d) relative to tetramethylsil-
ane and J-coupling in Hertz (Hz). Proton and carbon spectra were
typically obtained at room temperature. For TLC plates coated with
silica gel were run in ethyl acetate/hexane mixture and spots were
developed in ultraviolet (k = 254 nm).4.2. Synthesis of the meﬂoquine derivatives 1a–d and 2a–c
A toluene solution (5 ml) containing 0.3 g (0.8 mmol) of meﬂo-
quine, 0.96 mmol of the respective aldehyde, 1 g of molecular
sieves 4 Å and a catalytic amount of amberlyst 15 was heated un-
der reﬂux during 24–48 h. The consumption of meﬂoquine was fol-
lowed by TLC. The reaction mixture was ﬁltered through Celite and
concentrated to yield a semi-solid, which was triturated with cold
ethanol, in order to produce the pure product.
4.2.1. 4-[(1S,8aR)-3-(2,3-Dichlorophenyl)hexahydro[1,3]-
oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline
(1a)
Yield 58% as a white solid. m.p. 155–156 C. 1H NMR
[500.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.68 (1H; d;
J = 8.5 Hz; H5 or H7); 8.35 (1H; d; J = 7.5 Hz; H5 or H7); 7.98–7.94
(2H; m; H400 and H300 or H500); 7.85 (1H; s; H3); 7.75 (1H; dd; J = 8.0
and 1 Hz; H300 or H500); 7.61 (1H; t; J = 7.5 Hz; H6); 6.38 (1H; d;
J = 8.0 Hz; H10); 5.43 (1H; s; H110); 3.32 (1H; dddd; J = 11.0, 8.0 and
2.5 Hz; H20); 2.92 (1H; d; J = 10.5 Hz; H70 or H80); 2.19 (1H; ddd;
J = 13.5, 11.0 and 2.5 Hz; H70 or H80); 1.71 (1H; d; J = 12.0 Hz; H30
or H40); 1.65–1.57 (2H; m; H90 and H100); 1.43–1.27 (2H; m; H50
and H60); 0.38 (1H; dddd; J = 16.0, 12.0 and 4.0 Hz; H30 or H40) ppm.
13C NMR (125.0 MHz DMSO-d6) d 151.7; 144.4; 140.5; 137.8;
134.6; 134.2; 132.4; 130.3; 130.2; 129.8; 129.3; 128.4; 128.3;
125.4; 122.3; 119.2; 117.3; 93.8; 77.9; 66.9; 48.8; 27.8; 24.8;
24.3 ppm. LC/MS: m/z [M+H] = 536. IR mmax (cm1; KBr pellets):
1308 (C–O); 1181, 1141, 1110, 1080 (C–F). Anal. (C24H18Cll2F6N2O)
Theoretical: C, 53.85; H, 3.39; N, 5.23. Found: C, 54.26; H, 3.24; N,
5.16.
4.2.2. 4-[(1S,8aR)-3-(3,4-Dichlorophenyl)hexahydro[1,3]oxazolo-
[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (1b)
Yield 70% as a white solid. m.p. 184–185 C. 1H NMR
[500.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.68 (1H; d;
J = 10.5 Hz; H5 or H7); 8.35 (1H; d; J = 9.0 Hz; H5 or H7); 8.04
(1H; s; H3); 7.98–7.94 (2H; m; H100 or H400 or H500); 7.78–7.70 (2H;
m; H6 and H100 or H400 or H500); 6.33 (1H; d; J = 10.0 Hz; H10); 4.99
(1H; s; H110); 3.25 (1H; dddd; J = 13.5, 10.0 and 2.5 Hz; H20);
2.87–2.81 (1H; m; H70 or H80); 2.18–2.12 (1H; m; H70 or H80);
1.67–1.51 (3H; m; H30 or H40, H90 and H100); 1.38–1.23 (2H; m; H50
and H60); 0.39 (1H; dddd; J = 20.0, 15.5 and 4.5 Hz; H30 or H40) ppm.
13C NMR (125.0 MHz DMSO-d6) d 151.8; 144.1; 139.2; 133.9;
133.4; 132.0; 131.3; 130.4; 130.3; 129.8; 129.6; 128.5; 128.4;
117.1; 96.2; 77.7; 67.1; 48.5; 27.8; 24.8; 24.3 ppm. LC/MS: m/z
[M+H] = 536. IR mmax (cm1; KBr pellets): 1307 (C–O); 1211,
1182, 1151, 1134, 1112 (C–F). Anal. (C24H18Cll2F6N2O) Theoretical:
C, 53.85; H, 3.39; N, 5.23. Found: C, 53.99; H, 3.19; N, 5.23.
4.2.3. 4-[(1S,8aR)-3-(2,4-Dichlorophenyl)hexahydro[1,3]oxazolo-
[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (1c)
Yield 52% as a white solid. m.p. 162–163 C. 1H NMR
[400.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.68 (1H; d;
J = 8.0 Hz; H5 or H7); 8.36 (1H; d; J = 8.0 Hz; H5 or H7); 8.03–7.95
(2H; m; H6 and H200 or H400 or H500); 7.87 (1H; s; H3); 7.67–7.63
(2H; m; H200 or H400 or H500); 6.37 (1H; d; J = 8.0 Hz; H10); 5.39 (1H;
s; H110); 3.31 (1H; dddd; J = 12.0, 8.0 and 4.0 Hz; H20); 2.90–2.89
(1H; m; H70 or H80); 2.21–2.15 (1H; m; H70 or H80); 1.70 (1H; d;
J = 12.0 Hz; H30 or H40); 1.65–1.56 (2H; m; H90 and H100);
1.42–1.26 (2H; m; H50 and H60); 0.38 (1H; dddd; J = 16.0, 12.0 and
4.0 Hz; H30 or H40) ppm.
13C NMR (100.0 MHz DMSO-d6) d 151.8; 148.2; 144.0; 137.4;
136.4; 134.3; 131.3; 130.8; 130.4; 130.3; 129.8; 128.7; 128.5;
126.2; 123.5; 121.1; 117.2; 92.9; 77.8; 66.9; 48.7; 27.8; 24.8;
24.3 ppm. LC/MS: m/z [M+H] = 536. IR mmax (cm1; KBr pellets):
1308 (C–O); 1212, 1186, 1159, 1110, 1089 (C–F). Anal.
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53.83; H, 3.10; N, 5.26.
4.2.4. 4-[(1S,8aR)-3-(2,6-Dichlorophenyl)hexahydro[1,3]oxazolo-
[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (1d)
Yield 65% as a white solid. m.p. 224–225 C. 1H NMR
[200.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.63–8.59 (2H;
m); 8.35 (1H; d; J = 8.0 Hz; H5 or H7); 7.97 (1H; t; J = 8.0 Hz; H6);
7.57–7.45 (3H; m); 6.30 (1H; d; J = 10.0 Hz; H10); 5.75 (1H; s;
H110); 3.24–3.14 (1H; m; H20); 2.90–2.69 (1H; m; H70 or H80);
2.21–2.04 (1H; m; H70 or H80); 1.66–1.20 (5H; m; H50, H60, H90, H100
and H30 or H40); 0.53 (1H; dddd; J = 16.0, 12.0 and 4.0 Hz; H30 or
H40) ppm.
13C NMR (50.0 MHz DMSO-d6) d 151.1; 144.1; 139.4; 136.2;
132.5; 132.4; 130.6; 130.3; 130.1; 129.7; 129.1; 128.5; 128.3;
122.2; 117.2; 94.0; 76.9; 66.9; 48.2; 27.9; 24.8; 24.7 ppm. LC/MS:
m/z [M+H] = 536. IR mmax (cm1; KBr pellets): 1308 (C–O); 1215,
1188, 1140, 1108 (C–F). Anal. (C24H18Cll2F6N2O) Theoretical: C,
53.85; H, 3.39; N, 5.23. Found: C, 53.83; H, 3.49; N, 5.13.
4.2.5. 4-[(1S,8aR)-3-(5-Nitro-2-thienyl)hexahydro[1,3]oxazolo-
[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (2a)
Yield 50% as a brown solid. m.p. 160 C (dec.). 1H NMR
[500.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.67 (1H; d;
J = 8.3 Hz; H5 or H7); 8.36 (1H; d; J = 7.3 Hz; H5 or H7); 8.25 (1H;
s; H3); 8.09 (1H; d, J = 4.4 Hz; H300); 7.97 (1H; t; J = 7.8 Hz; H6);
7.55 (1H; d, J = 4.4 Hz; H400); 6.40 (1H; d; J = 8.3 Hz; H10); 5.34
(1H; s; H110); 3.33–3.31 (1H; m; H20); 3.03 (1H; d; J = 10.7 Hz; H70
or H80); 2.31–2.23 (1H; m; H70 or H80); 1.63–1.59 (3H; m; H30 or
H40, H90 and H100); 1.35–1.28 (2H; m; H50 and H60); 0.44–0.35 (1H;
m; H30 or H40) ppm.
13C NMR (50.0 MHz DMSO-d6) d 153.6; 151.1; 150.6; 148.6;
144.1; 130.4; 130.4; 130.3; 129.9; 129.8; 129.7; 129.4; 128.9;
128.5; 128.2; 127.4; 125.8; 123.7; 117.0; 92.4; 88.2; 78.9; 77.9;
67.1; 61.2; 48.6; 45.6; 27.7; 24.7; 24.2; 24.1; 23.9; 21.9 ppm. LC/
MS: m/z [M+H] = 518. IR mmax (cm1; KBr pellets): 1309 (C–O);
1266, 1212, 1188, 1147, 1110, 1087 (C–F). Anal. (C22H17F6N3O3S)
Theoretical: C, 51.07; H, 3.31; N, 8.12. Found: C, 50.92; H, 3.18; N
8.05.
4.2.6. 4-[(1S,8aR)-3-(5-Nitro-2-furyl)hexahydro[1,3]oxazolo[3,4-
a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (2b)
Yield 45% as a yellow solid. m.p. 185–186 C. 1H NMR
[500.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.68 (1H; d;
J = 8.5 Hz; H5 or H7); 8.35 (1H; d; J = 7.5 Hz; H5 or H7); 8.32 (1H;
s; H3); 7.96 (1H; t; J = 8.0 Hz; H6); 7.65 (1H; d; J = 3.5 Hz; H300);
7.15 (1H; d; J = 4.0 Hz; H400); 6.39 (1H; d; J = 8.0 Hz; H10); 5.14
(1H; s; H110); 3.21 (1H; dddd; J = 11.0, 8.0 and 2.5 Hz; H20); 3.01
(1H; d; J = 10.5 Hz; H70 or H80); 2.27–2.22 (1H; m; H70 or H80);
1.65 (1H; d; J = 12.5 Hz; H30 or H40); 1.61–1.57 (2H; m; H90 and
H100); 1.34–1.23 (2H; m; H50 and H60); 0.34 (1H; dddd; J = 15.5,
12.0 and 3.5 Hz; H30 or H40) ppm.
13C NMR (50.0 MHz DMSO-d6) d 154.8; 151.2; 130.3; 130.2;
129.6; 128.5; 128.3; 117.4; 114.6; 113.0; 90.5; 77.9; 66.9; 48.6;
27.4; 24.7; 24.1 ppm. LC/MS: m/z [M+H] = 502. IR mmax (cm1;
KBr pellets): 1306 (C–O); 1186, 1140, 1111 (C–F). Anal.
(C22H17F6N3O4) Theoretical: C, 52.70; H, 3.42; N, 8.38. Found: C,
52.81; H, 3.38; N, 8.37.
4.2.7. 4-[(1S,8aR)-3-(1H-Imidazol-2-yl)hexahydro[1,3]oxazolo-
[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (2c)
Yield 52% as a yellow solid. m.p. 210–212 C. 1H NMR
[400.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.67 (1H; d;
J = 8.0 Hz; H5 or H7); 8.48 (1H; s; H3); 8.34 (1H; d; J = 8.0 Hz; H5
or H7); 7.93 (1H; t; J = 8.0 Hz; H6); 7.25 (1H; sl; H200); 7.12 (1H;
sl; H300); 6.31 (1H; d; J = 8.0 Hz; H10); 5.10 (1H; s; H110); 3.19 (1H;dddd; J = 12.0, 8.0 and 4.0 Hz; H20); 2.95 (1H; d; J = 12.0 Hz; H70
or H80); 2.22–2.11 (1H; m; H70 or H80); 1.67–1.53 (3H; m; H3´ or
H40, H90 and H100); 1.35–1.22 (2H; m; H50 and H60); 0.37 (1H; dddd;
J = 16.0, 12.0 and 4.0 Hz; H30 or H40) ppm.
13C NMR (100.0 MHz DMSO-d6) d 150.7; 147.9; 133.5; 144.8;
143.0; 142.7; 129.2; 129.1; 128.8; 127.4; 127.3; 125.3; 124.4;
122.6; 117.0; 90.7; 76.6; 65.9; 47.7; 26.7; 23.7; 23.3 ppm. LC/MS:
m/z [M+H] = 457. IR mmax (cm1; KBr pellets): 1305 (C–O); 1212,
1184, 1144, 1112 (C–F). Anal. (C21H18F6N4O) Theoretical: C,
55.27; H, 3.98; N, 12.28. Found: C, 54.78; H, 3.98; N, 12.78.
4.3. Synthesis of the meﬂoquine derivatives 1e–g
A toluene solution (5 ml) containing 0.3 g (0.8 mmol) of meﬂo-
quine, 0.67 mmol of the respective aldehyde, 1 g of molecular
sieves 4 Å and a catalytic amount of amberlyst 15 was heated un-
der reﬂux during 24–48 h. The consumption of the aldehyde was
observed by TLC. After, the reaction mixture was ﬁltered through
Celite and concentrated to yield a semi-solid, which was puriﬁed
by chromatographic column using hexane/ethyl acetate as the
eluent.
4.3.1. 4-[(1S,8aR)-3-(2,3-Dimethoxyphenyl)hexahydro[1,3]oxazolo-
[3,4-a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (1e)
Yield 58% as a white solid. m.p. 130–131 C. 1H NMR
[400.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.68 (1H; d;
J = 8.0 Hz; H5 or H7); 8.35 (1H; d; J = 8.0 Hz; H5 or H7); 8.24 (1H;
s; H3); 7.96 (1H; t; J = 8.0 Hz; H6); 7.35 (1H; d; J = 3.0 Hz; H100);
7.24 (1H; dd; J = 8.0 and 3.0 Hz; H500); 7.08 (1H; d; J = 8.0 Hz;
H400); 6.26 (1H; d; J = 4.0 Hz; H10); 4.89 (1H; s; H110); 3.90 (3H; s;
OCH3); 3.88 (3H; s; OCH3); 3.20–3.15 (1H; m; H20); 2.94–2.90
(1H; m; H70 or H80); 2.09–2.05 (1H; m; H70 or H80); 1.63–1.53 (3H;
m; H30 or H40, H90 and H100) 1.36–1.25 (2H; m; H50 and H60); 0.38
(1H; dddd; J = 16.0, 12.0 and 4.0 Hz; H30 or H40) ppm.
13C NMR (50.0 MHz DMSO-d6) d 152.5; 151.5; 150.8; 148.4;
144.0; 130.3; 130.2; 129.8; 128.5; 128.4; 122.4; 117.4; 117.3;
112.6; 112.3; 97.9; 77.0; 67.1; 55.9; 56.2; 48.5; 27.8; 24.9;
24.4 ppm. LC/MS: m/z [M+H] = 527. IR mmax (cm1; KBr pellets):
1311 (C–O); 1172, 1136, 1107 (C–F). Anal. (C26H24F6N2O3) Theoret-
ical: C, 59.32; H, 4.59; N, 5.32. Found: C, 59.45; H, 4.68; N, 5.27.
4.3.2. 4-[(1S,8aR)-3-(3-Ethylphenyl)hexahydro[1,3]oxazolo[3,4-
a]pyridin-1-yl]-2,8-bis(triﬂuoromethyl)quinoline (1f)
Yield 55% as a white solid. m.p. 110–112 C. 1H NMR
[200.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.67 (1H; d;
J = 8.0 Hz; H5 or H7); 8.34 (1H; d; J = 6.0 Hz; H5 or H7); 8.22 (1H,
s); 7.95 (1H; t; J = 8.0 Hz); 7.44 (1H; t; J = 8.0 Hz); 7.30–7.27 (2H,
m); 7.05 (1H, d, J = 8.0 Hz); 6.28 (1H; d; J = 8.0 Hz; H10); 4.91 (1H;
s; H110); 4.14 (2H; q; J = 6.0 Hz; OCH2CH3); 3.23–3.14 (1H; m;
H20); 2.88–2.83 (1H; m; H70 or H80); 2.15–2.04 (1H; m; H70 or H80);
1.66–1.46 (3H; m; H30 or H40, H90 and H100); 1.42–1.16 (5H; m;
H50, H60 and OCH2CH3); 0.42–0.36 (1H; m; H30 or H40) ppm.
13C NMR (50.0 MHz DMSO-d6) d 160.6; 152.3; 144.0; 139.6;
130.7; 130.3; 130.2; 129.8; 128.4; 125.3; 121.6; 117.4; 116.6;
115.1; 97.8; 77.3; 67.1; 64.1; 48.5; 27.8; 24.9; 24.4; 15.2 ppm.
LC/MS: m/z [M+H] = 511. IR mmax (cm1; KBr pellets): 1307 (C–O);
1203, 1184, 1143, 1109, 1087 (C–F). Anal. (C26H24F6N2O2) Theoret-
ical: C, 61.17; H, 4.74; N, 5.49. Found: C, 61.10; H, 4.92; N, 5.51.
4.3.3. 2,8-bis(Triﬂuoromethyl)-4-[(1S,8aR)-3-(3,4,5-
trimethoxyphenyl)hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl]-
quinoline (1g)
Yield 72% as a white solid. m.p. 147–149 C. 1H NMR
[200.00 MHz (FIDRES ± 0.12 Hz), (CH3)2CO-d6] d: 8.68 (1H; d;
J = 8.0 Hz; H5 or H7); 8.35 (1H; d; J = 8.0 Hz; H5 or H7); 8.22 (1H;
s; H3); 7.96 (1H; t; J = 8.0 Hz; H6); 7.05 (2H; s; H100 and H500); 6.28
248 R. S. B. Gonçalves et al. / Bioorg. Med. Chem. 20 (2012) 243–248(1H; d; J = 8.0 Hz; H10); 4.89 (1H; s; H110); 3.92 (9H; s; OCH3); 3.24–
3.15 (1H; m; H20); 2.92–2.82 (1H; m; H70 or H80); 2.13–2.04 (1H; m;
H70 or H80); 1.64–1.43 (3H; m; H30 or H40, H90 and H100); 1.37–1.23
(2H; m; H50 and H60); 0.47–0.31 (1H; m; H30 or H40) ppm.
13C NMR (50.0 MHz DMSO-d6) d 154.9; 152.4; 149.0; 148.2;
144.1; 140.3; 133.4; 130.3; 130.2; 129.8; 128.4; 117.2; 107.6;
106.6; 98.0; 77.1; 67.13; 60.6; 56.7; 56.4; 48.6; 27.8; 24.9;
24.4 ppm. LC/MS: m/z [M+H] = 557. IR mmax (cm1; KBr pellets):
1305 (C–O); 1232, 1211, 1180, 1163, 1128, 1111 (C–F). Anal.
(C27H26F6N2O4) Theoretical: C, 58.27; H, 4.71; N, 5.03. Found: C,
58.13; H, 4.24; N, 5.01.
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